While there has not been much in the literature specifically for BCORL1 or ERBB4 as potential therapeutic targets in the context of GBM, there have been suggestions for studying a FDA-approved olapirib, a PARP inhibitor that has been shown to be brain permeable, to be used for PALB2 mutated GBM patients.34 The significance of these genetic mutations in GBM patient outcome may warrant further studies on specific mutations within these genes and related genes in similar pathways in the context of gliomas. Here, BCORL1 is linked to central nervous system cancer.